today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy ...

Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring.

Shares of Novavax Inc. NVAX slid 2.86% to $12.56 Wednesday, on what proved to be an all-around dismal trading session for the ...

Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based ...

Novavax's stock has been surging this year after announcing news of a collaboration with Sanofi. The company recently reported a profit, but whether it can stay out of the red is still a big ...

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know.

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $12.78 which represents a slight increase of $1.15 or 9.89% from the prior close of $11.63. The stock opened at $11.76 and touched a low ...

Market Open. Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Novavax Inc. NVAX slid 2.05% to $12.93 Tuesday, on what proved to be an all-around mixed trading session for the ...

That makes the stock inherently risky, considering if things don't go Novavax's way, the biotech's shares might fall off a cliff. So, although Novavax opened a new chapter, its long-term prospects ...